Global Radiopharmaceuticals for PET and SPECT Imaging Supply, Demand and Key Producers, 2026-2032
The global Radiopharmaceuticals for PET and SPECT Imaging market size is expected to reach $ 11227 million by 2032, rising at a market growth of 6.5% CAGR during the forecast period (2026-2032).
Radiopharmaceuticals for PET and SPECT Imaging are specialized radioactive compounds used as diagnostic tracers in nuclear medicine imaging procedures. These agents consist of a biologically active molecule labeled with a radionuclide, allowing physicians to visualize physiological, biochemical, and molecular processes within the body. In Positron Emission Tomography (PET), commonly used isotopes include fluorine-18, carbon-11, gallium-68, and zirconium-89, while Single Photon Emission Computed Tomography (SPECT) primarily utilizes technetium-99m, iodine-123, and thallium-201. These radiopharmaceuticals are widely employed in oncology, cardiology, neurology, and infection imaging, enabling early disease detection, diagnosis, treatment planning, and therapeutic monitoring.
The global Fluorine-18 market is experiencing steady expansion, driven primarily by the rising prevalence of chronic diseases such as cancer, Alzheimer?s, and cardiovascular disorders. As the gold standard radionuclide for Positron Emission Tomography (PET) imaging, Fluorine-18 benefits from its 110-minute half-life, which allows for efficient centralized production and distribution. Market growth is further propelled by the adoption of precision medicine, the expansion of cyclotron infrastructure, and the continuous development of novel radiotracers beyond traditional FDG. While North America remains the dominant region due to its advanced healthcare infrastructure and high utilization of PET/CT systems, the Asia-Pacific region is emerging as the fastest-growing market, fueled by significant investments in nuclear medicine and increasing healthcare accessibility. Future market trends emphasize the integration of AI in diagnostic imaging, the rise of 'theranostics,' and a strategic shift toward localized, hospital-adjacent cyclotron facilities to optimize supply chain efficiency.
This report studies the global Radiopharmaceuticals for PET and SPECT Imaging demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radiopharmaceuticals for PET and SPECT Imaging, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radiopharmaceuticals for PET and SPECT Imaging that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radiopharmaceuticals for PET and SPECT Imaging total market, 2021-2032, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Radiopharmaceuticals for PET and SPECT Imaging total market, key domestic companies, and share, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging revenue by player, revenue and market share 2021-2026, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging total market by Type, CAGR, 2021-2032, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Radiopharmaceuticals for PET and SPECT Imaging market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ANSTO, Rosatom, Eckert & Ziegler, CNNC, Curium Pharma, GE HealthCare, Jubilant Radiopharma, Cardinal Health, IBA, Sumitomo Heavy Industries, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Radiopharmaceuticals for PET and SPECT Imaging market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Radiopharmaceuticals for PET and SPECT Imaging Market, By Region:
1. How big is the global Radiopharmaceuticals for PET and SPECT Imaging market?
2. What is the demand of the global Radiopharmaceuticals for PET and SPECT Imaging market?
3. What is the year over year growth of the global Radiopharmaceuticals for PET and SPECT Imaging market?
4. What is the total value of the global Radiopharmaceuticals for PET and SPECT Imaging market?
5. Who are the Major Players in the global Radiopharmaceuticals for PET and SPECT Imaging market?
6. What are the growth factors driving the market demand?
Radiopharmaceuticals for PET and SPECT Imaging are specialized radioactive compounds used as diagnostic tracers in nuclear medicine imaging procedures. These agents consist of a biologically active molecule labeled with a radionuclide, allowing physicians to visualize physiological, biochemical, and molecular processes within the body. In Positron Emission Tomography (PET), commonly used isotopes include fluorine-18, carbon-11, gallium-68, and zirconium-89, while Single Photon Emission Computed Tomography (SPECT) primarily utilizes technetium-99m, iodine-123, and thallium-201. These radiopharmaceuticals are widely employed in oncology, cardiology, neurology, and infection imaging, enabling early disease detection, diagnosis, treatment planning, and therapeutic monitoring.
The global Fluorine-18 market is experiencing steady expansion, driven primarily by the rising prevalence of chronic diseases such as cancer, Alzheimer?s, and cardiovascular disorders. As the gold standard radionuclide for Positron Emission Tomography (PET) imaging, Fluorine-18 benefits from its 110-minute half-life, which allows for efficient centralized production and distribution. Market growth is further propelled by the adoption of precision medicine, the expansion of cyclotron infrastructure, and the continuous development of novel radiotracers beyond traditional FDG. While North America remains the dominant region due to its advanced healthcare infrastructure and high utilization of PET/CT systems, the Asia-Pacific region is emerging as the fastest-growing market, fueled by significant investments in nuclear medicine and increasing healthcare accessibility. Future market trends emphasize the integration of AI in diagnostic imaging, the rise of 'theranostics,' and a strategic shift toward localized, hospital-adjacent cyclotron facilities to optimize supply chain efficiency.
This report studies the global Radiopharmaceuticals for PET and SPECT Imaging demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radiopharmaceuticals for PET and SPECT Imaging, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radiopharmaceuticals for PET and SPECT Imaging that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radiopharmaceuticals for PET and SPECT Imaging total market, 2021-2032, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Radiopharmaceuticals for PET and SPECT Imaging total market, key domestic companies, and share, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging revenue by player, revenue and market share 2021-2026, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging total market by Type, CAGR, 2021-2032, (USD Million)
Global Radiopharmaceuticals for PET and SPECT Imaging total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Radiopharmaceuticals for PET and SPECT Imaging market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ANSTO, Rosatom, Eckert & Ziegler, CNNC, Curium Pharma, GE HealthCare, Jubilant Radiopharma, Cardinal Health, IBA, Sumitomo Heavy Industries, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Radiopharmaceuticals for PET and SPECT Imaging market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Radiopharmaceuticals for PET and SPECT Imaging Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Positron Emitters
- Gamma Emitters
- Cyclotron-produced
- Reactor/Generator-produced
- High Specific Activity
- Low Specific Activity
- Hospital
- Medical Imaging Center
- Other
- ANSTO
- Rosatom
- Eckert & Ziegler
- CNNC
- Curium Pharma
- GE HealthCare
- Jubilant Radiopharma
- Cardinal Health
- IBA
- Sumitomo Heavy Industries
- Sinotau
- Nueclear Healthcare
- DC Pharma
1. How big is the global Radiopharmaceuticals for PET and SPECT Imaging market?
2. What is the demand of the global Radiopharmaceuticals for PET and SPECT Imaging market?
3. What is the year over year growth of the global Radiopharmaceuticals for PET and SPECT Imaging market?
4. What is the total value of the global Radiopharmaceuticals for PET and SPECT Imaging market?
5. Who are the Major Players in the global Radiopharmaceuticals for PET and SPECT Imaging market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Radiopharmaceuticals for PET and SPECT Imaging Introduction
1.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Radiopharmaceuticals for PET and SPECT Imaging Total Market by Region (by Headquarter Location)
1.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.3 China Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.4 Europe Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.5 Japan Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.6 South Korea Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.7 ASEAN Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.8 India Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.2 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region
2.2.1 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026)
2.2.2 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Region (2027-2032)
2.3 United States Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.4 China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.5 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.6 Japan Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.7 South Korea Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.8 ASEAN Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.9 India Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
3 WORLD RADIOPHARMACEUTICALS FOR PET AND SPECT IMAGING COMPANIES COMPETITIVE ANALYSIS
3.1 World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radiopharmaceuticals for PET and SPECT Imaging Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radiopharmaceuticals for PET and SPECT Imaging in 2025
3.2.3 Global Concentration Ratios (CR8) for Radiopharmaceuticals for PET and SPECT Imaging in 2025
3.3 Radiopharmaceuticals for PET and SPECT Imaging Company Evaluation Quadrant
3.4 Radiopharmaceuticals for PET and SPECT Imaging Market: Overall Company Footprint Analysis
3.4.1 Radiopharmaceuticals for PET and SPECT Imaging Market: Region Footprint
3.4.2 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
3.4.3 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Comparison
4.2.1 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Radiopharmaceuticals for PET and SPECT Imaging Companies and Market Share, 2021-2026
4.3.1 United States Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026)
4.4 China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue and Market Share, 2021-2026
4.4.1 China Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026)
4.5 Rest of World Based Radiopharmaceuticals for PET and SPECT Imaging Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Positron Emitters
5.2.2 Gamma Emitters
5.3 Market Segment by Type
5.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type (2021-2026)
5.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type (2027-2032)
5.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY PRODUCED
6.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Produced: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Produced
6.2.1 Cyclotron-produced
6.2.2 Reactor/Generator-produced
6.3 Market Segment by Produced
6.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced (2021-2026)
6.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced (2027-2032)
6.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Produced (2027-2032)
7 MARKET ANALYSIS BY SPECIFIC ACTIVITY
7.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Specific Activity: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Specific Activity
7.2.1 High Specific Activity
7.2.2 Low Specific Activity
7.3 Market Segment by Specific Activity
7.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity (2021-2026)
7.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity (2027-2032)
7.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Specific Activity (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Medical Imaging Center
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2021-2026)
8.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2027-2032)
8.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 ANSTO
9.1.1 ANSTO Details
9.1.2 ANSTO Major Business
9.1.3 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.1.4 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 ANSTO Recent Developments/Updates
9.1.6 ANSTO Competitive Strengths & Weaknesses
9.2 Rosatom
9.2.1 Rosatom Details
9.2.2 Rosatom Major Business
9.2.3 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.2.4 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Rosatom Recent Developments/Updates
9.2.6 Rosatom Competitive Strengths & Weaknesses
9.3 Eckert & Ziegler
9.3.1 Eckert & Ziegler Details
9.3.2 Eckert & Ziegler Major Business
9.3.3 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.3.4 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Eckert & Ziegler Recent Developments/Updates
9.3.6 Eckert & Ziegler Competitive Strengths & Weaknesses
9.4 CNNC
9.4.1 CNNC Details
9.4.2 CNNC Major Business
9.4.3 CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.4.4 CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 CNNC Recent Developments/Updates
9.4.6 CNNC Competitive Strengths & Weaknesses
9.5 Curium Pharma
9.5.1 Curium Pharma Details
9.5.2 Curium Pharma Major Business
9.5.3 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.5.4 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Curium Pharma Recent Developments/Updates
9.5.6 Curium Pharma Competitive Strengths & Weaknesses
9.6 GE HealthCare
9.6.1 GE HealthCare Details
9.6.2 GE HealthCare Major Business
9.6.3 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.6.4 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 GE HealthCare Recent Developments/Updates
9.6.6 GE HealthCare Competitive Strengths & Weaknesses
9.7 Jubilant Radiopharma
9.7.1 Jubilant Radiopharma Details
9.7.2 Jubilant Radiopharma Major Business
9.7.3 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.7.4 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Jubilant Radiopharma Recent Developments/Updates
9.7.6 Jubilant Radiopharma Competitive Strengths & Weaknesses
9.8 Cardinal Health
9.8.1 Cardinal Health Details
9.8.2 Cardinal Health Major Business
9.8.3 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.8.4 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Cardinal Health Recent Developments/Updates
9.8.6 Cardinal Health Competitive Strengths & Weaknesses
9.9 IBA
9.9.1 IBA Details
9.9.2 IBA Major Business
9.9.3 IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.9.4 IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 IBA Recent Developments/Updates
9.9.6 IBA Competitive Strengths & Weaknesses
9.10 Sumitomo Heavy Industries
9.10.1 Sumitomo Heavy Industries Details
9.10.2 Sumitomo Heavy Industries Major Business
9.10.3 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.10.4 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Sumitomo Heavy Industries Recent Developments/Updates
9.10.6 Sumitomo Heavy Industries Competitive Strengths & Weaknesses
9.11 Sinotau
9.11.1 Sinotau Details
9.11.2 Sinotau Major Business
9.11.3 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.11.4 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Sinotau Recent Developments/Updates
9.11.6 Sinotau Competitive Strengths & Weaknesses
9.12 Nueclear Healthcare
9.12.1 Nueclear Healthcare Details
9.12.2 Nueclear Healthcare Major Business
9.12.3 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.12.4 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Nueclear Healthcare Recent Developments/Updates
9.12.6 Nueclear Healthcare Competitive Strengths & Weaknesses
9.13 DC Pharma
9.13.1 DC Pharma Details
9.13.2 DC Pharma Major Business
9.13.3 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.13.4 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 DC Pharma Recent Developments/Updates
9.13.6 DC Pharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Radiopharmaceuticals for PET and SPECT Imaging Industry Chain
10.2 Radiopharmaceuticals for PET and SPECT Imaging Upstream Analysis
10.3 Radiopharmaceuticals for PET and SPECT Imaging Midstream Analysis
10.4 Radiopharmaceuticals for PET and SPECT Imaging Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Radiopharmaceuticals for PET and SPECT Imaging Introduction
1.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Radiopharmaceuticals for PET and SPECT Imaging Total Market by Region (by Headquarter Location)
1.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.3 China Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.4 Europe Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.5 Japan Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.6 South Korea Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.7 ASEAN Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.3.8 India Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.2 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region
2.2.1 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026)
2.2.2 World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Region (2027-2032)
2.3 United States Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.4 China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.5 Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.6 Japan Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.7 South Korea Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.8 ASEAN Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
2.9 India Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032)
3 WORLD RADIOPHARMACEUTICALS FOR PET AND SPECT IMAGING COMPANIES COMPETITIVE ANALYSIS
3.1 World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radiopharmaceuticals for PET and SPECT Imaging Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radiopharmaceuticals for PET and SPECT Imaging in 2025
3.2.3 Global Concentration Ratios (CR8) for Radiopharmaceuticals for PET and SPECT Imaging in 2025
3.3 Radiopharmaceuticals for PET and SPECT Imaging Company Evaluation Quadrant
3.4 Radiopharmaceuticals for PET and SPECT Imaging Market: Overall Company Footprint Analysis
3.4.1 Radiopharmaceuticals for PET and SPECT Imaging Market: Region Footprint
3.4.2 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
3.4.3 Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Comparison
4.2.1 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Radiopharmaceuticals for PET and SPECT Imaging Companies and Market Share, 2021-2026
4.3.1 United States Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026)
4.4 China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue and Market Share, 2021-2026
4.4.1 China Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026)
4.5 Rest of World Based Radiopharmaceuticals for PET and SPECT Imaging Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Positron Emitters
5.2.2 Gamma Emitters
5.3 Market Segment by Type
5.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type (2021-2026)
5.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type (2027-2032)
5.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY PRODUCED
6.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Produced: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Produced
6.2.1 Cyclotron-produced
6.2.2 Reactor/Generator-produced
6.3 Market Segment by Produced
6.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced (2021-2026)
6.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced (2027-2032)
6.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Produced (2027-2032)
7 MARKET ANALYSIS BY SPECIFIC ACTIVITY
7.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Specific Activity: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Specific Activity
7.2.1 High Specific Activity
7.2.2 Low Specific Activity
7.3 Market Segment by Specific Activity
7.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity (2021-2026)
7.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity (2027-2032)
7.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Specific Activity (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Medical Imaging Center
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2021-2026)
8.3.2 World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2027-2032)
8.3.3 World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 ANSTO
9.1.1 ANSTO Details
9.1.2 ANSTO Major Business
9.1.3 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.1.4 ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 ANSTO Recent Developments/Updates
9.1.6 ANSTO Competitive Strengths & Weaknesses
9.2 Rosatom
9.2.1 Rosatom Details
9.2.2 Rosatom Major Business
9.2.3 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.2.4 Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Rosatom Recent Developments/Updates
9.2.6 Rosatom Competitive Strengths & Weaknesses
9.3 Eckert & Ziegler
9.3.1 Eckert & Ziegler Details
9.3.2 Eckert & Ziegler Major Business
9.3.3 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.3.4 Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Eckert & Ziegler Recent Developments/Updates
9.3.6 Eckert & Ziegler Competitive Strengths & Weaknesses
9.4 CNNC
9.4.1 CNNC Details
9.4.2 CNNC Major Business
9.4.3 CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.4.4 CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 CNNC Recent Developments/Updates
9.4.6 CNNC Competitive Strengths & Weaknesses
9.5 Curium Pharma
9.5.1 Curium Pharma Details
9.5.2 Curium Pharma Major Business
9.5.3 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.5.4 Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Curium Pharma Recent Developments/Updates
9.5.6 Curium Pharma Competitive Strengths & Weaknesses
9.6 GE HealthCare
9.6.1 GE HealthCare Details
9.6.2 GE HealthCare Major Business
9.6.3 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.6.4 GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 GE HealthCare Recent Developments/Updates
9.6.6 GE HealthCare Competitive Strengths & Weaknesses
9.7 Jubilant Radiopharma
9.7.1 Jubilant Radiopharma Details
9.7.2 Jubilant Radiopharma Major Business
9.7.3 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.7.4 Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Jubilant Radiopharma Recent Developments/Updates
9.7.6 Jubilant Radiopharma Competitive Strengths & Weaknesses
9.8 Cardinal Health
9.8.1 Cardinal Health Details
9.8.2 Cardinal Health Major Business
9.8.3 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.8.4 Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Cardinal Health Recent Developments/Updates
9.8.6 Cardinal Health Competitive Strengths & Weaknesses
9.9 IBA
9.9.1 IBA Details
9.9.2 IBA Major Business
9.9.3 IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.9.4 IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 IBA Recent Developments/Updates
9.9.6 IBA Competitive Strengths & Weaknesses
9.10 Sumitomo Heavy Industries
9.10.1 Sumitomo Heavy Industries Details
9.10.2 Sumitomo Heavy Industries Major Business
9.10.3 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.10.4 Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Sumitomo Heavy Industries Recent Developments/Updates
9.10.6 Sumitomo Heavy Industries Competitive Strengths & Weaknesses
9.11 Sinotau
9.11.1 Sinotau Details
9.11.2 Sinotau Major Business
9.11.3 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.11.4 Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Sinotau Recent Developments/Updates
9.11.6 Sinotau Competitive Strengths & Weaknesses
9.12 Nueclear Healthcare
9.12.1 Nueclear Healthcare Details
9.12.2 Nueclear Healthcare Major Business
9.12.3 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.12.4 Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Nueclear Healthcare Recent Developments/Updates
9.12.6 Nueclear Healthcare Competitive Strengths & Weaknesses
9.13 DC Pharma
9.13.1 DC Pharma Details
9.13.2 DC Pharma Major Business
9.13.3 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
9.13.4 DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 DC Pharma Recent Developments/Updates
9.13.6 DC Pharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Radiopharmaceuticals for PET and SPECT Imaging Industry Chain
10.2 Radiopharmaceuticals for PET and SPECT Imaging Upstream Analysis
10.3 Radiopharmaceuticals for PET and SPECT Imaging Midstream Analysis
10.4 Radiopharmaceuticals for PET and SPECT Imaging Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Radiopharmaceuticals for PET and SPECT Imaging Players in 2025
Table 12. World Radiopharmaceuticals for PET and SPECT Imaging Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Radiopharmaceuticals for PET and SPECT Imaging Company Evaluation Quadrant
Table 14. Head Office of Key Radiopharmaceuticals for PET and SPECT Imaging Players
Table 15. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
Table 16. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
Table 17. Radiopharmaceuticals for PET and SPECT Imaging Mergers & Acquisitions Activity
Table 18. United States VS China Radiopharmaceuticals for PET and SPECT Imaging Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share (2021-2026)
Table 23. China Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share (2021-2026)
Table 26. Rest of World Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share (2021-2026)
Table 29. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type (2027-2032) & (USD Million)
Table 32. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced, (USD Million), 2021 & 2025 & 2032
Table 33. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Value by Produced (2021-2026) & (USD Million)
Table 34. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced (2027-2032) & (USD Million)
Table 35. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity, (USD Million), 2021 & 2025 & 2032
Table 36. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Value by Specific Activity (2021-2026) & (USD Million)
Table 37. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity (2027-2032) & (USD Million)
Table 38. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2021-2026) & (USD Million)
Table 40. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2027-2032) & (USD Million)
Table 41. ANSTO Basic Information, Manufacturing Base and Competitors
Table 42. ANSTO Major Business
Table 43. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 44. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. ANSTO Recent Developments/Updates
Table 46. ANSTO Competitive Strengths & Weaknesses
Table 47. Rosatom Basic Information, Manufacturing Base and Competitors
Table 48. Rosatom Major Business
Table 49. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 50. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Rosatom Recent Developments/Updates
Table 52. Rosatom Competitive Strengths & Weaknesses
Table 53. Eckert & Ziegler Basic Information, Manufacturing Base and Competitors
Table 54. Eckert & Ziegler Major Business
Table 55. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 56. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Eckert & Ziegler Recent Developments/Updates
Table 58. Eckert & Ziegler Competitive Strengths & Weaknesses
Table 59. CNNC Basic Information, Manufacturing Base and Competitors
Table 60. CNNC Major Business
Table 61. CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 62. CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. CNNC Recent Developments/Updates
Table 64. CNNC Competitive Strengths & Weaknesses
Table 65. Curium Pharma Basic Information, Manufacturing Base and Competitors
Table 66. Curium Pharma Major Business
Table 67. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 68. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Curium Pharma Recent Developments/Updates
Table 70. Curium Pharma Competitive Strengths & Weaknesses
Table 71. GE HealthCare Basic Information, Manufacturing Base and Competitors
Table 72. GE HealthCare Major Business
Table 73. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 74. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. GE HealthCare Recent Developments/Updates
Table 76. GE HealthCare Competitive Strengths & Weaknesses
Table 77. Jubilant Radiopharma Basic Information, Manufacturing Base and Competitors
Table 78. Jubilant Radiopharma Major Business
Table 79. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 80. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Jubilant Radiopharma Recent Developments/Updates
Table 82. Jubilant Radiopharma Competitive Strengths & Weaknesses
Table 83. Cardinal Health Basic Information, Manufacturing Base and Competitors
Table 84. Cardinal Health Major Business
Table 85. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 86. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Cardinal Health Recent Developments/Updates
Table 88. Cardinal Health Competitive Strengths & Weaknesses
Table 89. IBA Basic Information, Manufacturing Base and Competitors
Table 90. IBA Major Business
Table 91. IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 92. IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. IBA Recent Developments/Updates
Table 94. IBA Competitive Strengths & Weaknesses
Table 95. Sumitomo Heavy Industries Basic Information, Manufacturing Base and Competitors
Table 96. Sumitomo Heavy Industries Major Business
Table 97. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 98. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Sumitomo Heavy Industries Recent Developments/Updates
Table 100. Sumitomo Heavy Industries Competitive Strengths & Weaknesses
Table 101. Sinotau Basic Information, Manufacturing Base and Competitors
Table 102. Sinotau Major Business
Table 103. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 104. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Sinotau Recent Developments/Updates
Table 106. Sinotau Competitive Strengths & Weaknesses
Table 107. Nueclear Healthcare Basic Information, Manufacturing Base and Competitors
Table 108. Nueclear Healthcare Major Business
Table 109. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 110. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Nueclear Healthcare Recent Developments/Updates
Table 112. Nueclear Healthcare Competitive Strengths & Weaknesses
Table 113. DC Pharma Basic Information, Manufacturing Base and Competitors
Table 114. DC Pharma Major Business
Table 115. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 116. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. DC Pharma Recent Developments/Updates
Table 118. DC Pharma Competitive Strengths & Weaknesses
Table 119. Global Key Players of Radiopharmaceuticals for PET and SPECT Imaging Upstream (Raw Materials)
Table 120. Global Radiopharmaceuticals for PET and SPECT Imaging Typical Customers
Table 1. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Radiopharmaceuticals for PET and SPECT Imaging Players in 2025
Table 12. World Radiopharmaceuticals for PET and SPECT Imaging Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Radiopharmaceuticals for PET and SPECT Imaging Company Evaluation Quadrant
Table 14. Head Office of Key Radiopharmaceuticals for PET and SPECT Imaging Players
Table 15. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Type Footprint
Table 16. Radiopharmaceuticals for PET and SPECT Imaging Market: Company Product Application Footprint
Table 17. Radiopharmaceuticals for PET and SPECT Imaging Mergers & Acquisitions Activity
Table 18. United States VS China Radiopharmaceuticals for PET and SPECT Imaging Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share (2021-2026)
Table 23. China Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share (2021-2026)
Table 26. Rest of World Based Radiopharmaceuticals for PET and SPECT Imaging Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share (2021-2026)
Table 29. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type (2027-2032) & (USD Million)
Table 32. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced, (USD Million), 2021 & 2025 & 2032
Table 33. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Value by Produced (2021-2026) & (USD Million)
Table 34. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced (2027-2032) & (USD Million)
Table 35. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity, (USD Million), 2021 & 2025 & 2032
Table 36. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Value by Specific Activity (2021-2026) & (USD Million)
Table 37. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity (2027-2032) & (USD Million)
Table 38. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2021-2026) & (USD Million)
Table 40. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application (2027-2032) & (USD Million)
Table 41. ANSTO Basic Information, Manufacturing Base and Competitors
Table 42. ANSTO Major Business
Table 43. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 44. ANSTO Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. ANSTO Recent Developments/Updates
Table 46. ANSTO Competitive Strengths & Weaknesses
Table 47. Rosatom Basic Information, Manufacturing Base and Competitors
Table 48. Rosatom Major Business
Table 49. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 50. Rosatom Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Rosatom Recent Developments/Updates
Table 52. Rosatom Competitive Strengths & Weaknesses
Table 53. Eckert & Ziegler Basic Information, Manufacturing Base and Competitors
Table 54. Eckert & Ziegler Major Business
Table 55. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 56. Eckert & Ziegler Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Eckert & Ziegler Recent Developments/Updates
Table 58. Eckert & Ziegler Competitive Strengths & Weaknesses
Table 59. CNNC Basic Information, Manufacturing Base and Competitors
Table 60. CNNC Major Business
Table 61. CNNC Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 62. CNNC Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. CNNC Recent Developments/Updates
Table 64. CNNC Competitive Strengths & Weaknesses
Table 65. Curium Pharma Basic Information, Manufacturing Base and Competitors
Table 66. Curium Pharma Major Business
Table 67. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 68. Curium Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Curium Pharma Recent Developments/Updates
Table 70. Curium Pharma Competitive Strengths & Weaknesses
Table 71. GE HealthCare Basic Information, Manufacturing Base and Competitors
Table 72. GE HealthCare Major Business
Table 73. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 74. GE HealthCare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. GE HealthCare Recent Developments/Updates
Table 76. GE HealthCare Competitive Strengths & Weaknesses
Table 77. Jubilant Radiopharma Basic Information, Manufacturing Base and Competitors
Table 78. Jubilant Radiopharma Major Business
Table 79. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 80. Jubilant Radiopharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Jubilant Radiopharma Recent Developments/Updates
Table 82. Jubilant Radiopharma Competitive Strengths & Weaknesses
Table 83. Cardinal Health Basic Information, Manufacturing Base and Competitors
Table 84. Cardinal Health Major Business
Table 85. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 86. Cardinal Health Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Cardinal Health Recent Developments/Updates
Table 88. Cardinal Health Competitive Strengths & Weaknesses
Table 89. IBA Basic Information, Manufacturing Base and Competitors
Table 90. IBA Major Business
Table 91. IBA Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 92. IBA Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. IBA Recent Developments/Updates
Table 94. IBA Competitive Strengths & Weaknesses
Table 95. Sumitomo Heavy Industries Basic Information, Manufacturing Base and Competitors
Table 96. Sumitomo Heavy Industries Major Business
Table 97. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 98. Sumitomo Heavy Industries Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Sumitomo Heavy Industries Recent Developments/Updates
Table 100. Sumitomo Heavy Industries Competitive Strengths & Weaknesses
Table 101. Sinotau Basic Information, Manufacturing Base and Competitors
Table 102. Sinotau Major Business
Table 103. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 104. Sinotau Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Sinotau Recent Developments/Updates
Table 106. Sinotau Competitive Strengths & Weaknesses
Table 107. Nueclear Healthcare Basic Information, Manufacturing Base and Competitors
Table 108. Nueclear Healthcare Major Business
Table 109. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 110. Nueclear Healthcare Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Nueclear Healthcare Recent Developments/Updates
Table 112. Nueclear Healthcare Competitive Strengths & Weaknesses
Table 113. DC Pharma Basic Information, Manufacturing Base and Competitors
Table 114. DC Pharma Major Business
Table 115. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Product and Services
Table 116. DC Pharma Radiopharmaceuticals for PET and SPECT Imaging Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. DC Pharma Recent Developments/Updates
Table 118. DC Pharma Competitive Strengths & Weaknesses
Table 119. Global Key Players of Radiopharmaceuticals for PET and SPECT Imaging Upstream (Raw Materials)
Table 120. Global Radiopharmaceuticals for PET and SPECT Imaging Typical Customers
LIST OF FIGURES
Figure 1. Radiopharmaceuticals for PET and SPECT Imaging Picture
Figure 2. World Radiopharmaceuticals for PET and SPECT Imaging Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Radiopharmaceuticals for PET and SPECT Imaging Total Revenue (2021-2032) & (USD Million)
Figure 4. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 13. Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 16. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 18. China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 23. India Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Radiopharmaceuticals for PET and SPECT Imaging by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radiopharmaceuticals for PET and SPECT Imaging Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radiopharmaceuticals for PET and SPECT Imaging Markets in 2025
Figure 27. United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Type in 2025
Figure 31. Positron Emitters
Figure 32. Gamma Emitters
Figure 33. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Type (2021-2032)
Figure 34. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced, (USD Million), 2021 & 2025 & 2032
Figure 35. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Produced in 2025
Figure 36. Cyclotron-produced
Figure 37. Reactor/Generator-produced
Figure 38. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Produced (2021-2032)
Figure 39. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity, (USD Million), 2021 & 2025 & 2032
Figure 40. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Specific Activity in 2025
Figure 41. High Specific Activity
Figure 42. Low Specific Activity
Figure 43. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Specific Activity (2021-2032)
Figure 44. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 45. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Application in 2025
Figure 46. Hospital
Figure 47. Medical Imaging Center
Figure 48. Other
Figure 49. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Application (2021-2032)
Figure 50. Radiopharmaceuticals for PET and SPECT Imaging Industrial Chain
Figure 51. Methodology
Figure 52. Research Process and Data Source
Figure 1. Radiopharmaceuticals for PET and SPECT Imaging Picture
Figure 2. World Radiopharmaceuticals for PET and SPECT Imaging Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Radiopharmaceuticals for PET and SPECT Imaging Total Revenue (2021-2032) & (USD Million)
Figure 4. World Radiopharmaceuticals for PET and SPECT Imaging Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Radiopharmaceuticals for PET and SPECT Imaging Revenue (2021-2032) & (USD Million)
Figure 13. Radiopharmaceuticals for PET and SPECT Imaging Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 16. World Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 18. China Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 23. India Radiopharmaceuticals for PET and SPECT Imaging Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Radiopharmaceuticals for PET and SPECT Imaging by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radiopharmaceuticals for PET and SPECT Imaging Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radiopharmaceuticals for PET and SPECT Imaging Markets in 2025
Figure 27. United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Radiopharmaceuticals for PET and SPECT Imaging Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Type in 2025
Figure 31. Positron Emitters
Figure 32. Gamma Emitters
Figure 33. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Type (2021-2032)
Figure 34. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Produced, (USD Million), 2021 & 2025 & 2032
Figure 35. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Produced in 2025
Figure 36. Cyclotron-produced
Figure 37. Reactor/Generator-produced
Figure 38. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Produced (2021-2032)
Figure 39. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Specific Activity, (USD Million), 2021 & 2025 & 2032
Figure 40. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Specific Activity in 2025
Figure 41. High Specific Activity
Figure 42. Low Specific Activity
Figure 43. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Specific Activity (2021-2032)
Figure 44. World Radiopharmaceuticals for PET and SPECT Imaging Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 45. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Application in 2025
Figure 46. Hospital
Figure 47. Medical Imaging Center
Figure 48. Other
Figure 49. World Radiopharmaceuticals for PET and SPECT Imaging Market Size Market Share by Application (2021-2032)
Figure 50. Radiopharmaceuticals for PET and SPECT Imaging Industrial Chain
Figure 51. Methodology
Figure 52. Research Process and Data Source
